Thailand Peptides
Get in Contact
Catalog
PeptidesCategories
Research
CompareInformation
Calculator
Get in Contact
Comparison · GH Secretagogue

CJC-1295 vs Ipamorelin

CJC-1295 and Ipamorelin are the two halves of the most-referenced GH-secretagogue stack. One is a GHRH analog with an extended half-life; the other is a selective ghrelin-receptor agonist. The mechanistic question is whether to use either alone or combine them, and the answer is the reason the stack became canonical.

Bangkok research desk ·

Side-by-side

CJC-1295 Ipamorelin
MechanismModified GHRH(1-29) with DAC; extended half-life; elevates IGF-1 baseline.Selective GHS-R1a agonist; GH-specific; minimal cortisol or prolactin effect.
Half-life~8 days (DAC variant).~2 hours.
Dose1-2 mg/week SC.200-300 mcg × 2-3 daily SC.
Cycle12 weeks on / 4 off.12 weeks on / 4 off.
Research contextProlonged GH and IGF-1 stimulation in human volunteers1.Selective GH release without off-target endocrine effects2.
Cost tierMid (low weekly dose, higher per-mg).Low-to-mid.

CJC-1295 and Ipamorelin target the two complementary pathways that drive endogenous GH release. CJC-1295 is a modified GHRH(1-29) with a drug affinity complex (DAC) that extends its half-life to approximately eight days, so a single weekly injection elevates the circulating GHRH tone. Ipamorelin is a pentapeptide that agonises the GHS-R1a receptor (the ghrelin receptor) with unusual selectivity, driving pulsatile GH release without the cortisol or prolactin elevation seen with earlier GHS compounds2.

Alone, each compound has a clear profile. CJC-1295 raises baseline IGF-1 and sustains it; this is confirmed in human volunteer data1. Ipamorelin produces sharper GH pulses but without an elevated baseline, and it preserves the physiological pulsatile pattern. The clinical question in most research protocols is which profile suits the endpoint: sustained baseline elevation favours body-composition or IGF-1-driven endpoints; pulsatile release favours sleep-architecture or acute-recovery endpoints.

Combined, the two compounds target different receptors and can amplify GH output beyond either alone. The standard research protocol uses CJC-1295 once or twice weekly alongside Ipamorelin two to three times daily. The combined regimen mimics physiological pulsatility better than either alone and is the pairing most commonly referenced in GH-secretagogue research protocols. See the full treatment in the Ipamorelin vs CJC-1295 mechanism deep-dive and GH secretagogue cycle design.

Frequently asked

Do CJC-1295 and Ipamorelin work better together?
The combined regimen is the most commonly referenced research stack because the two compounds target complementary receptors. CJC-1295 raises baseline GHRH tone; Ipamorelin drives pulsatile GHS-R1a-mediated release. Using both together produces GH kinetics closer to physiological pulsatility than either alone.
Why is Ipamorelin considered "cleaner"?
Ipamorelin is selective for GHS-R1a without appreciable agonism at receptors that drive cortisol, prolactin, or appetite. This selectivity was one of the main findings in the original characterisation2.
Is the 12-weeks-on / 4-weeks-off protocol evidence-based?
The cycling protocol is derived from the broader GH-secretagogue research tradition, not a specific trial. It reflects a conservative approach to receptor desensitisation and pituitary feedback, not a rigorous trial-derived schedule.
Research desk
Ordering both CJC-1295 and Ipamorelin for a research protocol? The Bangkok desk handles pricing, COA, and timing on WhatsApp.
Open a line with the research desk ≥98% HPLC purity · supplier COA on file · Bangkok-based

Go deeper

Related comparisons

References

  1. Teichman SL, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295. J Clin Endocrinol Metab. 2006. PMID: 16352683
  2. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PMID: 9849822

All references verified against PubMed via NCBI E-utilities.